Skip to main content
ARS Home » Southeast Area » Athens, Georgia » U.S. National Poultry Research Center » Endemic Poultry Viral Diseases Research » Research » Publications at this Location » Publication #327084
Title: Construction of recombinant Newcastle disease virus expressing the S1 protein of Turkey enteric coronavirus for use as a bivalent vaccine

Author
item LI, YUFENG - Shandong Poultry Research Institute, China
item ZHANG, ZHENYU - Northeast Agricultural University
item Day, James
item YANG, JINLONG - Chongqing Academy Of Animal Sciences
item Zsak, Laszlo
item Yu, Qingzhong

Submitted to: Southeastern Regional Virology Conference
Publication Type: Abstract Only
Publication Acceptance Date: 3/18/2016
Publication Date: 4/10/2016
Citation: Li, Y., Zhang, Z., Day, J.M., Yang, J., Zsak, L., Yu, Q. 2016. Construction of recombinant Newcastle disease virus expressing the S1 protein of Turkey enteric coronavirus for use as a bivalent vaccine[Abstract]. 14th Southeastern Regional Virology Conference, Atlanta, GA, April 8-10, 2016.

Interpretive Summary:

Technical Abstract: Turkey enteric coronavirus (TCoV) causes a contagious form of enteritis in turkeys, generally recognized in the field by outward signs including diarrhea and decreased weight gain, resulting in severe economic losses for the poultry industry in the US. To date there is no commercial vaccine available to control this economically important disease. In this study, we aimed to develop a Newcastle disease virus (NDV) vectored recombinant vaccine against TCoV disease and Newcastle disease (ND). An infectious clone of an enterotropic NDV vaccine strain, V4, was constructed using In-Fusion cloning techniques. The major antigenic spike glycoprotein S1 subunit of TCoV North Carolina 2012 strain were cloned and inserted into the intergenic region between the P and M genes in the V4 infectious clone. The recombinant virus, rV4/TCoV-S1, was rescued using reverse genetics technology. Biological assessment of the recombinant virus by performing the standard mean death time (MDT) and intracerebral pathogenicity index (ICPI) tests, titration, and sequence analysis showed that rV4/TCoV-S1 maintained lentogenic pathotype with similar growth dynamics, stability, and virus titers in vitro when compared to the parental V4 virus. Expression of TCoV S1 protein in the recombinant virus-infected cells was detected by immunofluorescence assay. The results of the study suggested that the rV4/TCoV-S1 virus are safe and stable, and warrant for a vaccination/challenge clinical trail in turkeys to evaluate the vaccine efficacy against ND and TCoV disease.